Insulin Resistance: The Silent Root of Most Chronic Disease

Insulin resistance is arguably the most consequential metabolic disturbance of our time. It precedes Type 2 diabetes by 10–15 years, underlies non-alcoholic fatty liver disease, polycystic ovary syndrome, hypertension, dyslipidaemia, and accelerates cardiovascular disease. Most people develop it silently, without any symptoms, while their routine fasting glucose remains in the normal range. Understanding insulin resistance — what it is, how to measure it, and how to reverse it — is foundational to preventive metabolic medicine.

What Is Insulin Resistance?

Insulin is a peptide hormone secreted by pancreatic beta cells in response to rising blood glucose. Its primary role is to facilitate glucose uptake into cells — particularly skeletal muscle (which accounts for 75–80% of post-meal glucose disposal), the liver (which stores glucose as glycogen), and adipose tissue (which uses glucose for triglyceride synthesis).^[1]

Insulin resistance develops when these target tissues lose their sensitivity to insulin signalling. The insulin receptor is still present, but the downstream intracellular signalling cascade — involving IRS-1 phosphorylation, PI3K activation, and GLUT4 translocation to the cell membrane — becomes impaired.^[2] The cell no longer efficiently extracts glucose from the bloodstream in response to normal insulin concentrations.

The pancreas compensates by secreting more insulin — a state called hyperinsulinaemia. For years, blood glucose appears normal because the pancreas is producing 2–5 times the usual amount of insulin to maintain it. It is only when beta cells can no longer sustain this compensation that fasting glucose rises and diabetes is diagnosed. But the underlying metabolic derangement has been present for over a decade.^[3]

The Upstream Causes of Insulin Resistance

Insulin resistance is driven by a convergence of factors:

• Ectopic fat accumulation: Excess lipid deposition in the liver (hepatic steatosis) and skeletal muscle interferes directly with insulin signalling by activating protein kinase C isoforms that phosphorylate IRS-1 on serine residues rather than tyrosine, impairing the signalling cascade.^[4]
• Chronic low-grade inflammation: Visceral adipose tissue secretes pro-inflammatory cytokines — TNF-α and IL-6 in particular — that directly inhibit insulin receptor signalling in muscle and liver.^[5]
• Mitochondrial dysfunction: Impaired mitochondrial oxidative capacity in skeletal muscle reduces the ability to oxidise fatty acids, leading to intramyocellular lipid accumulation and insulin resistance.^[6]
• Gut microbiome dysbiosis: Altered gut microbiota composition affects short-chain fatty acid production, intestinal permeability (increasing LPS translocation and systemic inflammation), and bile acid metabolism — all of which modulate insulin sensitivity.^[7]
• Sleep deprivation and cortisol excess: A single night of 4 hours of sleep raises cortisol sufficiently to reduce peripheral insulin sensitivity by 30–40% the following day.^[8]

The Downstream Cascade: What Hyperinsulinaemia Does

Chronically elevated insulin has profound systemic consequences beyond glucose dysregulation:^[9,10]

• Visceral fat accumulation: Insulin is a potent anabolic hormone that promotes fat storage, particularly in visceral depots which express high concentrations of insulin receptors.
• Dyslipidaemia: Hyperinsulinaemia stimulates hepatic VLDL-triglyceride production, raises small dense LDL particles, and suppresses HDL.
• Hypertension: Insulin promotes renal sodium retention and activates the sympathetic nervous system, raising blood pressure.
• PCOS: Hyperinsulinaemia stimulates ovarian androgen production, disrupting the LH/FSH ratio and driving the hormonal profile of polycystic ovary syndrome.
• Non-alcoholic fatty liver disease: Hepatic insulin resistance drives excess de novo lipogenesis in the liver.
• Cancer risk: Insulin and IGF-1 are potent mitogenic signals. Chronic hyperinsulinaemia has been associated with increased risk of breast, colorectal, endometrial, and pancreatic cancers.^[11]

Measuring Insulin Resistance: The HOMA-IR Score

The gold standard for measuring insulin resistance is the hyperinsulinaemic-euglycaemic clamp, a technically demanding research procedure. For clinical practice, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the validated surrogate:^[12]

HOMA-IR = (Fasting Insulin [mIU/L] × Fasting Glucose [mmol/L]) ÷ 22.5

Or in mg/dL units: HOMA-IR = (Fasting Insulin × Fasting Glucose) ÷ 405

Interpretation: Below 1.0 is optimal; 1.0–2.0 is normal; 2.0–2.5 is borderline; above 2.5 is significant insulin resistance requiring intervention. HOMA-IR above 3.0 correlates strongly with metabolic syndrome and predictsa 5–10 times higher risk of developing Type 2 diabetes within 5 years.^[13]

Importantly, HOMA-IR detects insulin resistance years before HbA1c or fasting glucose become abnormal. We routinely test fasting insulin as part of our metabolic panel — a test that is conspicuously absent from most standard annual health checks.

Reversing Insulin Resistance: The Evidence-Based Interventions

Insulin resistance is highly responsive to lifestyle intervention. The interventions with the strongest evidence, ranked by magnitude of HOMA-IR reduction in clinical trials:

1. Significant weight loss (10%+ body weight): Reduces HOMA-IR by 40–60% through reduction of ectopic fat and visceral adiposity.^[14]
2. Progressive resistance training: Increases GLUT4 expression in skeletal muscle independently of weight loss, improving insulin-mediated glucose disposal by 25–40%.^[15]
3. Low-carbohydrate diet (<130g/day): Reduces postprandial insulin demand directly; HOMA-IR reductions of 30–45% reported at 12 weeks.^[16]
4. Time-restricted eating: Improves insulin sensitivity through circadian alignment of glucose metabolism; HOMA-IR reductions of 15–25% at 12 weeks.^[17]
5. Sleep optimisation (7–9 hours): Reverses cortisol-mediated insulin resistance within days of improved sleep quality.^[8]
6. Metformin: Reduces hepatic glucose output; 15–20% HOMA-IR reduction. Useful adjunct but inferior to lifestyle change as monotherapy.^[18]